跳至主要内容
临床试验/NCT02995083
NCT02995083撤回早期 1 期

Corticosteriods vs. Saline vs. Air Placebo Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial

Rush University Medical Center0 个研究点开始时间: 2017年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
撤回
主要终点
Mean change in Western Ontario and McMaster Universities Arthritis Index score (WOMAC)

研究概览

简要总结

To investigate the clinical benefit of intra-articular injections of saline in patients with symptomatic osteoarthritis of the knee and compare the clinical response of saline to the current standard treatment with corticosteroids and an air injection placebo.

详细描述

As non-surgical treatments of OA are essential, multiple trials have been done to compare standard of care IA injection therapies to more novel injection treatments, with many of these trials using saline as the control arm. The purpose of using a control arm is to attempt to eliminate placebo effect and help distinguish the true effectiveness of a therapy. There has been controversy over the clinical effect of saline in treating OA with some arguing that saline may have some clinical benefit. If this is true, it could allow for the true effect of standard of care therapies to appear diminished when compared to saline as a placebo. A recent meta analysis looked at the use of saline as a placebo in 38 randomized control trials to determine if intra-articular saline injections for knee OA had a clinical effect. The study found that IA injections of saline significantly improved short-term knee pain in 32 of the studies which involved 1705 patients, p <0.001, and long-term pain was significantly decreased in 19 of the studies involving 1445 patients, p <0.001. It is essential to empirically determine if saline has a clinical effect due to the role it plays as a placebo in many clinical studies of the management of OA with intra-articular injections.

Objective: To investigate the clinical benefit of intra-articular injections of saline in patients with symptomatic osteoarthritis of the knee and compare the clinical response of saline to the current standard treatment with corticosteroids and an air injection placebo.

Study Design: Prospective, single-blinded, randomized, clinical study. Patients will be randomized into three treatment arms in a 1:1:1 fashion with approximately 50 patients in the saline arm, 50 patients in the corticosteroid arm, and 50 patients in the placebo arm.

Null Hypothesis: Clinical knee outcomes of subjects following one intra-articular knee injection of air will be similar to one intra-articular knee injection of saline or corticosteroid for symptomatic patients diagnosed with knee OA.

Statistical Assumptions: Power Analysis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient must be between the ages of 18 and 80
  • Informed consent has been obtained from the patient
  • The patient must have diagnosed symptomatic osteoarthritis of the tibio-femoral or patello-femoral compartment of the target knee for at least 1 month
  • The patient has moderate-to-severe knee pain reflected by an average visual analogue scale (VAS) score of 4 or greater (out of a possible 10) over the previous 7 days.
  • Radiographic imaging must show grade II-III osteoarthritis on the Kellgren & Lawrence Scale.
  • Patients may have bilateral osteoarthritis but only patients with unilateral symptoms may be included.

排除标准

  • Knee instability
  • A score less than 4 (out of a possible 10) on their intake VAS
  • Major axial deviation (>5º valgus or varus deviation as evidenced on a standard of care x-ray.
  • Previous surgery at the target knee < 6 months.
  • Symptomatic osteoarthritis of the contralateral knee or any other joint.
  • Systemic or intra articular injection to any joint with corticosteroids within 6 months prior to screening
  • Previous joint injection of any type in the past 6 months
  • Systemic conditions that could interfere with outcome such as Rheumatoid arthritis, coagulopathy, and anemia.
  • Allergy to any of the injected substances.
  • Any patient unable to cease NSAID usage (other than low dose aspirin) due to unrelated condition.
  • Cognitive impairment or unable to provide informed consent
  • Recent knee trauma with violation of the intra-articular bone.

研究组 & 干预措施

Knee injection with corticosteroids

Active Comparator

Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.

干预措施: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine (Drug)

Knee injection with saline

Placebo Comparator

Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.

干预措施: Normal Saline 10 ml (Drug)

Knee injection with air

Sham Comparator

Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.

干预措施: Air 10 ml (Drug)

结局指标

主要结局

Mean change in Western Ontario and McMaster Universities Arthritis Index score (WOMAC)

时间窗: 12 weeks after injection

Mean change in the WOMAC Index score from baseline score

次要结局

  • Mean change in Short Form 12 (SF-12) score(12 weeks after injection)
  • Mean change in International Knee Documentation Committee (IKDC) score(12 weeks after injection)
  • Mean change in Knee injury and Osteoarthritis Outcome Score (KOOS)(12 weeks after injection)
  • Mean change in Visual Analogue Scale (VAS)(12 weeks after injection)
  • Mean change in The Lysholm Knee score(12 weeks after injection)
  • Mean change in use of rescue medication(12 weeks after injection)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mukesh Ahuja

Certified Principal Investigator, Research Administrator

Rush University Medical Center

相似试验